L. brevis DSM27961 as a preventive strategy for Alzheimer’s disease
Alzheimer’s disease is a neurovegetative disorder that sees genetic predisposition and infectious processes among the leading etiological causes. Among the latter are gingivitis and periodontitis. A review by the Taiwanese group of Chun-Pin Chiang1 wanted to deepen the issue and collected 26 articles on the main scientific search engines. This association was verified from the epidemiological point of view and post-mortem studies. The gene sequencing of the microbial of the oral cavity presented a constant predominance of Gram-negative bacteria as elements of inflammation of the oral cavity. This element, suggested the use of a specific strain of L. brevis for its anti-inflammatory capacities. A study on laboratory mice in which gingivitis was experimentally induced demonstrated a significant reduction of inflammation levels by the determination of proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6, and IL7A) by the action of the enzyme argininedeiminase present in the strain L. brevis itself. These findings have also been confirmed in human studies by Lee JK et al.3. Click here for more publications.
The role that this specific strain of L. brevis might have in preventing the onset of periodontitis and gingivitis must now be re-evaluated in the most complex clinical picture of a scenario predisposing to Alzheimer’s disease.
Pr De Simone, About
- Mao, S. et al. Association of periodontitis and oral microbiomes with Alzheimer’s disease: A narrative systematic review. J Dent Sci 17, 1762–1779 (2022).
- Maekawa, T. & Hajishengallis, G. Topical treatment with probiotic Lactobacillus brevis CD2 inhibits experimental periodontal inflammation and bone loss. J Periodontal Res 49, 785–791 (2014).
- Lee, J.-K., Kim, S.-J., Ko, S.-H., Ouwehand, A. C. & Ma, D. S. Modulation of the host response by probiotic Lactobacillus brevis CD2 in experimental gingivitis. Oral diseases 21, 705–712 (2015).